RNA sequencing will be conducted to provide expression data and give relevance to DNA mutations. Quantitative proteomics analysis will be conducted to determine the exact amounts of specific proteins and to confirm expression of genes that are correlative of response and disease progression. All genomic, transcriptomic, and proteomic molecular analyses will be retrospective and exploratory. Plasma will be collected and circulat ing tumor RNA (ctRNA) will be isolated. A PCR -based assay (LiquidGenomicsDx) will be used to assess the level of PD -L1 cir culating RNA. The levels of PD-L1 ctRNA will be correlated with efficacy outcomes. Statistical Methods: This phase 1b /2 study will examine the overall safety profile and preliminary efficacy of metronomic combination therapy in subjects with pancreatic cancer patients whose tumors have progressed on or after SoC treatment . Results will be presented separately for the induc tion and maintenance phases of treatment as well as overall for the entire treatment regimen. Overall safety will be assessed by descriptive analyses using tabulated frequencies of AEs by grade using CTCAE version 4.03 in terms of treatment- emergent AEs, SAEs, and clinically significant changes in safety laboratory tests, physical examin ations, ECGs, and vital signs. ORR will be evaluated in accordance with RECIST Version 1.1 and irRC. The percentage of subjects (and 95% confidence interval [CI]) who achi eve a confirmed response will be summarized. DCR will be evaluated similar to ORR. PFS, OS , and DOR will be analyzed using Kaplan- Meier methods. Descriptive statistics of PROs will be presented. Correlations between genomic/proteomic profiles and efficacy outcomes will be assessed. Confidential and Proprietary 12 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Amendment 2 Figure 1: Study Treatment Schema Confidential and Proprietary 13 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Amendment 2 Confidential and Proprietary 14 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Amendment 2 Confidential and Proprietary 15